CT 1101 topical gel data

HYALF announced Phase III results in an Australian trial of 150 patients treated for up to three months, showing statistically significant efficacy.

Of 87 patients evaluated 30 days after therapy, 64 percent receiving drug had more than a 50 percent reduction in the number of lesions, compared to 29 percent of those who got placebo (p=0.002). ...